Why Peptide Certificates of Analysis Ensure Research Quality
As of June 1, 2026, the European Medicines Agency mandates that any impurity exceeding 0.1% in synthetic peptides must be reported on analytical…
As of June 1, 2026, the European Medicines Agency mandates that any impurity exceeding 0.1% in synthetic peptides must be reported on analytical…
Analytical validity is not a product feature. It’s a procedural outcome of batch-specific verification. In a market where generic documentation is…
A 99% purity claim on a static PDF is no longer a standard of proof. It’s a liability. In the 2026 research landscape, sourcing third-party tested…
A single impurity in your starting material can invalidate months of in-vitro data. Most researchers realize that relying on a generic certificate of…
A catalog specification is not a guarantee of analytical integrity. For researchers, relying on generic documentation is a risk that often leads to…
Analytical integrity isn’t a variable; it’s a requirement. If your laboratory results fluctuate between orders, the failure often lies in the…
A Certificate of Analysis is only as reliable as the specific lot it represents. Following the full enforcement of the FDA’s Final Guidance on…
In laboratory research, purity is not a marketing claim; it is a verifiable analytical measurement that must be documented for every batch. You…
In an era of 300% increases in FDA enforcement, the “research use only” label is no longer a shield for sub-standard analytical practices. If your…
Scientific integrity isn’t found in a product catalog. It’s found in the batch-specific verification of every single unit. For many laboratories, the…